Kura Oncology, Inc. last reported quarterly results on Aug 12, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $20.9 million (+36.5% year over year) and diluted EPS of -$0.77. It usually reports 12–43 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 3, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Nov 4, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–43 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 12, 2026
43 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
21
+36.5%
|
-68
-3.3%
|
-0.77
-2.7%
|
|
May 12, 2026
42 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
18
+29.5%
|
-73
-27.7%
|
-0.83
-25.8%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
17
|
-81
-321.5%
|
-0.92
-317.1%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
21
|
-74
-36.2%
|
-0.85
-34.9%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
15
|
-66
-30.1%
|
-0.75
-27.1%
|
|
May 1, 2025
31 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
14
|
-57
-16.0%
|
-0.66
-11.9%
|
|
Feb 26, 2025
57 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-19
+55.1%
|
-0.22
+60.1%
|
|
Nov 7, 2024
38 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
—
|
-54
-40.9%
|
-0.63
-26.0%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KURA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1422143
- Former names
- ZETA ACQUISITION CORP III (until Mar 10, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.